Efficacy and Safety of Ertapenem Sodium (MK-0826) Following Colorectal Surgery in Chinese Adults (MK-0826-056)

Inclusion Criteria: \- Participant is scheduled to undergo elective colon or colorectal surgery by laparotomy that is scheduled in advance with adequate time prior to surgery to complete preoperative bowel preparation. \- Participant is a Chinese adult between the ages of more than 18 years old and less than 81 years old. \- Participant is highly unlikely to conceive. Exclusion Criteria: * Participant is undergoing emergency colon or colorectal surgery. * Participant requires a second planned colorectal surgery or other surgery requiring antibiotic prophylaxis within the 4-week follow-up period. * Participant is undergoing laparoscopic-assisted surgery. * Participant is undergoing an isolated rectal procedure. * Participant has a decompensated intestinal obstruction. * Participant has active inflammatory bowel disease involving the colon (i.e., ulcerative colitis or Crohn's disease). * Participant is scheduled to undergo an elective colorectal procedure for revision of a previous operation involving a large bowel resection. * Participant has a bacterial infection at the time of surgery. * Participant requires or is anticipated to need the administration of other (nonstudy therapy) systemic antimicrobial therapy within 1 week prior to surgery or at any time during this study. * Participant is anticipated to receive either antibiotic or antiseptic peritoneal lavage during the surgery. * Participant has a history of serious allergy, hypersensitivity (e.g., anaphylaxis), or any serious reaction to ertapenem sodium, ceftriaxone sodium, metronidazole, penicillin, or any cephalosporin, beta(β)-lactam, or nitroimidazole agents. * Participant is breast feeding or plans to breast feed prior to the completion of the study period. * Participant has neutropenia. * Participant with immunosuppression due to an underlying disease, chronic immunosuppressive therapy, or use of high-dose corticosteroids. * Participant has a rapidly progressive or terminal illness. * Participant is considered unlikely to survive through the expected 4-week study period.